Assertio Therapeutics (NASDAQ:ASRT) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.07 by 214.29 percent. This is a 175 percent increase over earnings of $0.08 per share from the same period last year. The company reported quarterly sales of $34.21 million which beat the analyst consensus estimate of $31.33 million by 9.20 percent. This is a 34.31 percent increase over sales of $25.47 million the same period last year.
Can-Fite Novel Approach for the Treatment of Pancreatic Carcinoma with Namodenoson Receives Appreciation of the American Association of Cancer Research (AACR)
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncology, inflammatory and liver diseases, today announced that its study
